Karla Plevova
Overview
Explore the profile of Karla Plevova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svozilova H, Vojtova L, Matulova J, Bruknerova J, Polakova V, Radova L, et al.
PeerJ
. 2024 Dec;
12:e18637.
PMID: 39655330
Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia characterized by the accumulation of neoplastic mature B cells in blood, bone marrow, lymph nodes, and spleen. The disease biology...
2.
Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al.
J Clin Invest
. 2024 Oct;
134(23).
PMID: 39436708
Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL...
3.
Hagerstrand D, Oder B, Cortese D, Qu Y, Binzer-Panchal A, Osterholm C, et al.
Leukemia
. 2024 Sep;
38(11):2429-2442.
PMID: 39261602
SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1 and 17 SF3B1...
4.
Kurucova T, Reblova K, Janovska P, Porc J, Navrkalova V, Pavlova S, et al.
Mol Oncol
. 2024 May;
18(10):2541-2553.
PMID: 38770541
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of...
5.
Riba M, Sala C, Culhane A, Flobak A, Patocs A, Boye K, et al.
Nat Genet
. 2024 May;
56(5):733-736.
PMID: 38702538
No abstract available.
6.
Navrkalova V, Plevova K, Radova L, Porc J, Pal K, Malcikova J, et al.
Br J Haematol
. 2023 Dec;
204(1):240-249.
PMID: 38062779
Large-scale next-generation sequencing (NGS) studies revealed extensive genetic heterogeneity, driving a highly variable clinical course of chronic lymphocytic leukaemia (CLL). The evolution of subclonal populations contributes to diverse therapy responses...
7.
Vanova T, Sedmik J, Raska J, Amruz Cerna K, Taus P, Pospisilova V, et al.
Cell Rep
. 2023 Oct;
42(11):113310.
PMID: 37864790
During the past two decades, induced pluripotent stem cells (iPSCs) have been widely used to study human neural development and disease. Especially in the field of Alzheimer's disease (AD), remarkable...
8.
Mancikova V, Pesova M, Pavlova S, Helma R, Zavacka K, Hejret V, et al.
Mol Oncol
. 2022 Nov;
17(1):82-97.
PMID: 36334078
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild-type protein. We assessed the impact...
9.
Ondrouskova E, Bohunova M, Zavacka K, cech P, Smuharova P, Boudny M, et al.
Front Oncol
. 2022 Jul;
12:859618.
PMID: 35814434
Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of or , is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups...
10.
Jarousek R, Mikulova A, Dadova P, Taus P, Kurucova T, Plevova K, et al.
Biochim Biophys Acta Mol Cell Res
. 2022 Jul;
1869(10):119321.
PMID: 35779629
Single-cell transcriptomics has emerged as a powerful tool to investigate cells' biological landscape and focus on the expression profile of individual cells. Major advantage of this approach is an analysis...